Chugai Pharmaceutical Co., Ltd. (CHGCY)

OTCMKTS: CHGCY · Delayed Price · USD
-0.12 (-0.93%)
Jun 29, 2022 4:00 PM - Market closed
Market Cap 43.01B
Revenue (ttm) 8.72B
Net Income (ttm) 2.84B
Shares Out 3.34B
EPS (ttm) 0.87
PE Ratio 14.76
Forward PE 18.21
Dividend $0.33 (2.53%)
Ex-Dividend Date Jun 29, 2022
Volume 138,868
Open 12.55
Previous Close 12.99
Day's Range 12.55 - 13.01
52-Week Range 11.88 - 20.75
Beta 0.66
Analysts Buy
Price Target 16.58 (+28.8%)
Earnings Date n/a


Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product... [Read more...]

Industry Drug Manufacturers-General
Founded 1925
CEO Tatsuro Kosaka
Employees 7,664
Stock Exchange OTCMKTS
Ticker Symbol CHGCY
Full Company Profile

Analyst Forecast

According to 17 analysts, the average rating for CHGCY stock is "Buy." The 12-month stock price forecast is 16.58, which is an increase of 28.83% from the latest price.

Price Target
(28.83% upside)
Analyst Consensus: Buy
Stock Forecasts


There is no news available yet.